

The role of steroids in infection-related glomerulonephritis

Submission date 08/02/2021	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 28/02/2021	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 22/02/2021	Condition category Urological and Genital Diseases	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Infection-related glomerulonephritis is inflammation of the tiny filters in the kidneys (glomeruli) caused by infection. Given the role of immune activation in the disease, there has been interest in the use of immunosuppression to improve clinical outcomes. The aim of this study is to find out whether the use of steroids can improve renal (kidney) outcomes in patients with infection-related glomerulonephritis.

Who can participate?

Patients aged over 18 with infection-related glomerulonephritis

What does the study involve?

Participants are randomly allocated to receive either standard care or standard care plus corticosteroids. Participants allocated to corticosteroids are given intravenous methylprednisolone (into a vein) on 3 consecutive days, followed by oral prednisolone for 1 month, followed by a slow taper at 5 mg/week. Disease remission is assessed after 6 months, or at the time of the last follow-up, whichever is earlier.

What are the possible benefits and risks of participating?

The use of corticosteroids may improve renal outcomes in patients with infection-related glomerulonephritis. There is a potential risk of steroid toxicity.

Where is the study run from?

Institute of Nephrology, Rajiv Gandhi Government General Hospital (India)

When is the study starting and how long is it expected to run for?

April 2016 to December 2021

Who is funding the study?

Madras Medical College (India)

Who is the main contact?
Dr Tanuj Moses Lamech
tanujlamech@gmail.com

Contact information

Type(s)

Public

Contact name

Dr Tanuj Lamech

Contact details

Institute of Nephrology
Rajiv Gandhi Government General Hospital
Chennai
India
600 003
+91 (0)9840755250
tanujlamech@gmail.com

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

Nil known

Study information

Scientific Title

A randomized controlled trial of corticosteroids in infection-related glomerulonephritis

Study objectives

Infection-related glomerulonephritis is an immune-complex disease. This study tests the hypothesis that steroids ameliorate the deleterious consequences of immunological activation, and improve outcomes in patients with infection-related glomerulonephritis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 05/09/2017, Institutional Ethics Committee, Madras Medical College (Madras Medical College, EVR Periyar Salai, Park Town, Chennai 600 003, India; Telephone number: +91 (0)44 25363970; ethicsmmc@gmail.com), ref: 18092017

Study design

Open-label single-centre randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Infection-related glomerulonephritis

Interventions

Patients meeting the inclusion criteria are randomized 1:1, in blocks of 4, to receive either standard care (control arm), or standard care plus corticosteroids (intervention arm). Patients randomized to the intervention arm are given pulses of intravenous methylprednisolone (1 g) on 3 consecutive days. This is followed by oral prednisolone 1 mg/kg/day for 1 month, followed by a slow taper at 5 mg/week. No matching placebo was provided to the control arm, and the trial was open-label.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Methylprednisolone, prednisolone

Primary outcome measure

Complete remission, defined as an estimated glomerular filtration rate (eGFR) of >60 mL/min/1.73m², assessed at 6 months after randomisation, or at time of last follow-up, whichever is earlier

Secondary outcome measures

1. Combined complete remission (defined as eGFR >60 mL/min/1.73m² at 6 months) and partial remission (defined as serum creatinine lower than peak creatinine during initial admission, along with eGFR <60 mL/min/1.73m² at 6 months)

2. Death and end-stage renal disease (taken from the patient's medical records) at 6 months
3. Persistent proteinuria (urine PCR >0.5 or dipstick 2+ or more) at 6 months
4. Dialysis independence at any point within 6 months since randomization, among patients with dialysis-requiring renal failure at initial presentation (taken from the patient's medical records)

Overall study start date

01/04/2016

Completion date

30/11/2020

Eligibility

Key inclusion criteria

1. Patients older than 18 years who provide written informed consent
2. Fulfilment of 3/5 of the Nasr et al. criteria for infection-related glomerulonephritis
3. Serum creatinine >1.5 mg/dl at time of randomisation

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

86

Total final enrolment

86

Key exclusion criteria

1. More than 21 days elapsed since presentation
2. Presence of a contraindication for steroids
3. Seropositivity for HIV, hepatitis B, or hepatitis C
4. Hypocomplementaemia at 3 months
5. IgA-dominant infection-related glomerulonephritis
6. Crescents involving >50% of the sampled glomeruli
7. Diabetic nephropathy class III or IV
8. Interstitial fibrosis and tubular atrophy >40%

Date of first enrolment

06/09/2017

Date of final enrolment

31/05/2020

Locations

Countries of recruitment

India

Study participating centre

Rajiv Gandhi Government General Hospital

Park Town

Chennai

India

600 003

Sponsor information

Organisation

Madras Medical College

Sponsor details

Park Town

Chennai

India

600 003

+91 (0)8939732516

mmcnephro@gmail.com

Sponsor type

University/education

Website

<http://www.mmc.tn.gov.in/>

ROR

<https://ror.org/050ztxn78>

Funder(s)

Funder type

University/education

Funder Name

Results and Publications

Publication and dissemination plan

1. The study protocol will be available on request
2. Planned publication in a peer-reviewed journal

Intention to publish date

31/12/2021

Individual participant data (IPD) sharing plan

Data not available due to ethical/legal restrictions

IPD sharing plan summary

Not expected to be made available